Effects of nintedanib by inclusion criteria for progression of interstitial lung disease

BACKGROUND: The INBUILD trial investigated nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs). We investigated the decline in forced vital capacity (FVC) in subgroups based on the inclusion criteria for ILD progression. METHODS: Subjects had a fibrosin...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher, Toby M., Brown, Kevin K., Kreuter, Michael, Devaraj, Anand, Walsh, Simon L.F., Lancaster, Lisa H., Belloli, Elizabeth A., Padilla, Maria, Behr, Juergen, Goeldner, Rainer-Georg, Tetzlaff, Kay, Schlenker-Herceg, Rozsa, Flaherty, Kevin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812469/
https://www.ncbi.nlm.nih.gov/pubmed/34210788
http://dx.doi.org/10.1183/13993003.04587-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812469/
https://www.ncbi.nlm.nih.gov/pubmed/34210788
http://dx.doi.org/10.1183/13993003.04587-2020

Ejemplares similares